2023 was a troublesome calendar year for the biopharma sector, with quite a few companies downsizing and restructuring their workforces to stay afloat. There are actually signs of recovery, as mergers and acquisitions picked up through the pharmaceutical and lifestyle sciences field during the latter Component of 2023 and have https://sites.google.com/view/bio-sites/blog